Anna Apostolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4790985/publications.pdf

Version: 2024-02-01

236925 289244 1,677 55 25 40 citations h-index g-index papers 55 55 55 1724 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	1.7	183
2	Noninvasive Measurement of Cardiac Output During Exercise by Inert Gas Rebreathing Technique: A New Tool for Heart Failure Evaluation. Journal of the American College of Cardiology, 2005, 46, 1779-1781.	2.8	154
3	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€term comparison. European Journal of Heart Failure, 2018, 20, 700-710.	7.1	84
4	Spironolactone improves lung diffusion in chronic heart failure. European Heart Journal, 2005, 26, 159-164.	2.2	66
5	Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. International Journal of Cardiology, 2015, 189, 134-140.	1.7	66
6	Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial. International Journal of Cardiology, 2013, 168, 2134-2140.	1.7	65
7	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	3.9	60
8	Lung function with carvedilol and bisoprolol in chronic heart failure: Is \hat{l}^2 selectivity relevant?. European Journal of Heart Failure, 2007, 9, 827-833.	7.1	54
9	Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. European Journal of Heart Failure, 2006, 8, 729-735.	7.1	48
10	Chronotropic Incompentence and Functional Capacity in Chronic Heart Failure: No Role of <i>î²</i> â€Blockers and <i>î²</i> â€Blocker Dose. Cardiovascular Therapeutics, 2012, 30, 100-108.	2.5	45
11	Effects of \hat{l}^2 -blockers on ventilation efficiency in heart failure. American Heart Journal, 2010, 159, 1067-1073.	2.7	42
12	Relationship of resting hemoglobin concentration to peak oxygen uptake in heart failure patients. American Journal of Hematology, 2010, 85, 414-417.	4.1	40
13	Mechanisms of Periodic Breathing During Exercise in Patients With Chronic Heart Failure. Chest, 2008, 133, 197-203.	0.8	39
14	Lvad pump speed increase is associated with increased peak exercise cardiac output and vo2, postponed anaerobic threshold and improved ventilatory efficiency. International Journal of Cardiology, 2017, 230, 28-32.	1.7	39
15	A Non Invasive Estimate of Dead Space Ventilation from Exercise Measurements. PLoS ONE, 2014, 9, e87395.	2.5	39
16	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. International Journal of Cardiology, 2016, 203, 1067-1072.	1.7	36
17	Cardiopulmonary Exercise Testing in Adult Congenital Heart Disease. Annals of the American Thoracic Society, 2017, 14, S93-S101.	3.2	36
18	Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment. Journal of Sexual Medicine, 2009, 6, 2795-2805.	0.6	35

#	Article	IF	CITATIONS
19	Lungs in Heart Failure. Pulmonary Medicine, 2012, 2012, 1-9.	1.9	34
20	Acetazolamide and Inhaled Carbon Dioxide Reduce Periodic Breathing During Exercise in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2014, 20, 278-288.	1.7	34
21	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	2.2	33
22	Comprehensive effects of left ventricular assist device speed changes on alveolar gas exchange, sleep ventilatory pattern, and exercise performance. Journal of Heart and Lung Transplantation, 2018, 37, 1361-1371.	0.6	33
23	Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure. Circulation: Heart Failure, 2009, 2, 175-180.	3.9	32
24	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	1.8	32
25	Prognostic role of βâ€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	7.1	28
26	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	1.7	25
27	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	3.1	23
28	Cardiopulmonary evidence of exercise-induced silent ischaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 249-253.	2.8	21
29	Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19. European Journal of Preventive Cardiology, 2020, 27, 1127-1132.	1.8	21
30	Lateral Decubitus Position Generates Discomfort and Worsens Lung Function in Chronic Heart Failure. Chest, 2005, 128, 1511-1516.	0.8	20
31	Alveolar Membrane Conductance Decreases as BNP Increases During Exercise in Heart Failure. Rationale for BNP in the Evaluation of Dyspnea. Journal of Cardiac Failure, 2009, 15, 136-144.	1.7	20
32	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. Canadian Journal of Cardiology, 2016, 32, 754-759.	1.7	19
33	Influence of exertional oscillatory ventilation on exercise performance in heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 688-692.	2.8	18
34	Exercise physiology in pulmonary hypertension patients with and without congenital heart disease. European Journal of Preventive Cardiology, 2019, 26, 86-93.	1.8	18
35	The Effects of Anesthesia, Muscle Paralysis, and Ventilation on the Lung Evaluated by Lung Diffusion for Carbon Monoxide and Pulmonary Surfactant Protein B. Anesthesia and Analgesia, 2015, 120, 373-380.	2,2	17
36	Alveolar–capillary membrane diffusion measurement by nitric oxide inhalation in heart failure. European Journal of Preventive Cardiology, 2015, 22, 206-212.	1.8	16

3

#	Article	IF	Citations
37	Assessment of cardiac resynchronization therapy response. International Journal of Cardiology, 2009, 136, 240-242.	1.7	14
38	Acute Increase of CardiacÂOutput Reduces Central Sleep Apneas in Heart Failure Patients. Journal of the American College of Cardiology, 2015, 66, 2571-2572.	2.8	13
39	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	3.1	13
40	Inside ventilatory regulation in pulmonary hypertension: several hidden data are still undiscovered. European Journal of Preventive Cardiology, 2014, 21, 268-271.	1.8	9
41	Minute ventilation/carbon dioxide production in chronic heart failure. European Respiratory Review, 2021, 30, 200141.	7.1	7
42	Marginal donors and organ shortness: concomitant surgical procedures during heart transplantation: a literature review. Journal of Cardiovascular Medicine, 2022, 23, 167-175.	1.5	7
43	Roles of periodic breathing and isocapnic buffering period during exercise in heart failure. European Journal of Preventive Cardiology, 2020, 27, 19-26.	1.8	6
44	Use of a new diagnostic catheter for transradial internal mammary artery angiography early after minimally invasive coronary bypass. Catheterization and Cardiovascular Interventions, 2000, 50, 371-374.	1.7	5
45	Effects of left ventricular assist device on cardiopulmonary exercise performance. European Journal of Heart Failure, 2020, 22, 381-382.	7.1	5
46	Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach. Journal of Cardiac Failure, 2022, 28, 509-514.	1.7	5
47	ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism. Cardiovascular Drugs and Therapy, 2016, 30, 159-168.	2.6	4
48	Effects of \hat{l}^2 2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective \hat{l}^2 -blockers: a randomized trial. Scientific Reports, 2020, 10, 7101.	3.3	4
49	Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude. European Journal of Preventive Cardiology, 2012, 19, 444-451.	1.8	3
50	Variability in pulmonary diffusing capacity in heart failure. Respiratory Physiology and Neurobiology, 2020, 280, 103473.	1.6	3
51	Successful Open Chest Epicardial Ablation for Refractory Ventricular Tachycardia in an LVADÂRecipient. JACC: Case Reports, 2021, 3, 1055-1060.	0.6	2
52	Exertional Oscillatory Ventilation and Central Sleep Apnea in Heart Failure: Siblings, Cousins, or What Else?., 2017,, 183-202.		1
53	Week to week variability of pulmonary capillary blood volume and alveolar membrane diffusing capacity in patients with heart failure. Respiratory Physiology and Neurobiology, 2021, 290, 103679.	1.6	1
54	Reply to commentary on: Confusion in reporting pulmonary diffusion capacity for nitric oxide and the alveolar-capillary membrane conductance for nitric oxide. European Journal of Preventive Cardiology, 2015, 22, 314-316.	1.8	0

#	Article	IF	CITATIONS
55	Why do left ventricular assist device recipients remain heart failure patients? Reply. European Journal of Heart Failure, 2020, 22, 1055-1055.	7.1	O